{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:08Z","timestamp":1649203208813},"reference-count":11,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.neurobiolaging.2011.05.020","type":"journal-article","created":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T23:29:37Z","timestamp":1310167777000},"page":"2326.e1-2326.e4","source":"Crossref","is-referenced-by-count":0,"title":["Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice"],"prefix":"10.1016","volume":"32","author":[{"given":"Saskia N.","family":"Sivananthan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blair R.","family":"Leavitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2011.05.020_bib1","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0899-9007(00)00392-0","article-title":"Eicosapentaenoic acid (EPA): an antiinflammatory omega-3 fat with potential clinical applications","volume":"16","author":"Babcock","year":"2000","journal-title":"Nutrition"},{"key":"10.1016\/j.neurobiolaging.2011.05.020_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ana.410310202","article-title":"Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses","volume":"31","author":"Beal","year":"1992","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.05.020_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0306-4522(01)00409-2","article-title":"Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease","volume":"109","author":"Clifford","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurobiolaging.2011.05.020_bib4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.nut.2004.06.017","article-title":"Essential fatty acids in Huntington's disease","volume":"20","author":"Das","year":"2004","journal-title":"Nutrition"},{"key":"10.1016\/j.neurobiolaging.2011.05.020_bib5","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2011.05.020_bib6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1471-4159.2004.02726.x","article-title":"Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation","volume":"91","author":"Fox","year":"2004","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neurobiolaging.2011.05.020_bib7","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0022-2275(20)37159-5","article-title":"Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism","volume":"38","author":"Fr\u00f8yland","year":"1997","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.neurobiolaging.2011.05.020_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00001756-200201210-00029","article-title":"MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment","volume":"13","author":"Puri","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.neurobiolaging.2011.05.020_bib9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.neurobiolaging.2011.05.020_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1471-4159.2005.03357.x","article-title":"Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington's disease","volume":"95","author":"Van Raamsdonk","year":"2005","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neurobiolaging.2011.05.020_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.expneurol.2005.07.021","article-title":"Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease","volume":"196","author":"Van Raamsdonk","year":"2005","journal-title":"Exp. Neurol"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019745801100203X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019745801100203X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T20:34:53Z","timestamp":1638045293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019745801100203X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S019745801100203X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.05.020","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}